Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03068910 · ClinicalTrials.gov registry record · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
A Early Phase 1 study of Polycystic Ovary Syndrome and Puberty, sponsored by University of Virginia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03068910 is a Early Phase 1 study of Polycystic Ovary Syndrome and Puberty that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 32 participants, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03068910, a Early Phase 1 study of Polycystic Ovary Syndrome and Puberty, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone pulse frequency (primary endpoint).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Spironolactone
- DRUG Micronized progesterone
Study Locations (1)
Virginia
- University of Virginia Clinical Research Unit - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-07-21 |
| Est. Completion | 2025-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03068910
The ClinicalTrials.gov registry entry for NCT03068910 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Polycystic Ovary Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03068910 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03068910 about?
NCT03068910 is a clinical study titled "Hyperandrogenemia and Altered Day-night LH Pulse Patterns". The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone pulse frequency (primary endpoint).
What is the current status of trial NCT03068910?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2016-07-21. Estimated completion is 2025-12-01.
What conditions does trial NCT03068910 study?
This clinical trial studies the following conditions: Polycystic Ovary Syndrome, Puberty, Hyperandrogenism.
What interventions are being tested in trial NCT03068910?
The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG), Micronized progesterone (DRUG).
Who is sponsoring clinical trial NCT03068910?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03068910 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycystic Ovary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
RECRUITING · Early Phase 1
-
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
RECRUITING · Early Phase 1
-
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
RECRUITING · Early Phase 1
-
Combined Oral Contraceptive Pill and Resistance Starch
RECRUITING · Phase 2
-
The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
RECRUITING · NA
-
Apple Women's Health Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.